Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment
NCT ID: NCT04292756
Last Updated: 2022-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
63 participants
INTERVENTIONAL
2018-03-27
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
NCT00071227
Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery
NCT00801450
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
NCT00101764
Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema
NCT02556424
Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT00443521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is planned as a follow-up. Patients with with serous pigment epithelial detachment associated with age-related macular degeneration included in it will receive triamcinolone acetonide in accordance with the approved indications for use indicated in the instructions for the use of drugs in Ukraine.
The treatment proposed in this study is based on the world experience and scientific developments of the Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine ". Therefore, it is expected that the benefit / risk ratio in relation to the participation in this study should not be different from that described in the scientific literature and the benefits outweigh the risk. It is known that the absence of treatment in these diseases leads to an irreparable loss of central vision.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triamcinolone Acetonide 40 mg
Arm 1
Subtenon injection of 40 mg triamcinolone acetonide
Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Visometry
Ophthalmic examination
Fluorescent angiography
Ophthalmic examination
Refractometry
Ophthalmic examination
Slit lamp examination
Ophthalmic examination
Ophthalmoscopy
Ophthalmic examination
OKT
Ophthalmic examination
IOP
Ophthalmic examination
Triamcinolone Acetonide 4 mg
Arm 2
Intravitreal injection of 4 mg triamcinolone acetonide
Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Visometry
Ophthalmic examination
Fluorescent angiography
Ophthalmic examination
Refractometry
Ophthalmic examination
Slit lamp examination
Ophthalmic examination
Ophthalmoscopy
Ophthalmic examination
OKT
Ophthalmic examination
IOP
Ophthalmic examination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Subtenon injection of 40 mg triamcinolone acetonide
Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Intravitreal injection of 4 mg triamcinolone acetonide
Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
Visometry
Ophthalmic examination
Fluorescent angiography
Ophthalmic examination
Refractometry
Ophthalmic examination
Slit lamp examination
Ophthalmic examination
Ophthalmoscopy
Ophthalmic examination
OKT
Ophthalmic examination
IOP
Ophthalmic examination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent form.
* Men and women ≥ 50 years of age.
* Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
* Naive serous pigment epithelial detachment associated with AMD as defined on FA and OCT.
* Transparent optical media and possibility to mydriasis.
* Best corrected visual acuity at least 20/100 Equivalent of Snellen (ETDRS).
* Absence of signs of CNV, angiomatous retina proliferation, polypoid choriovasculopathy defined on FA and OCT.
Exclusion Criteria
* Previous intravitreal injections of anti-VEGF drugs in the study eye.
* Any injections of corticosteroids (intravitreal, subtenon, subconjunctival or parabulbar) or implantation of medical device in the study eye.
* Ocular inflammation or external ocular inflammation in the study eye.
* Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period.
* Any ocular disorder in the study eye that, in the opinion of the investigator, may confound interpretation of the study results.
* Significant scarring or atrophy in the fovea that indicates substantial irreversible vision loss in the study eye.
* Evidence at examination of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye or current treatment for serious systemic infection.
* Vitreomacular traction or traction retinal detachment, epiretinal membrane in study eye.
* Any iris neovascularization and/or vitreous hemorrhage in either eye.
* Uncontrolled glaucoma, or previous filtration surgery in either eye.
* Maсular hole.
* Any prior treatment with photodynamic therapy in the study eye.
* Cataract surgery within 3 months prior to Day 1 in the study eye.
* Yttrium-aluminum-garnet laser capsulotomy within 2 months prior to Day 1 in the study eye.
* Any other intraocular surgery within 3 months prior to Day 1 in the study eye.
* History of vitreoretinal surgery and/or scleral buckle surgery in the study eye.
* Previous assignment to treatment during this study.
* Uncontrolled hypertension.
* History of cerebrovascular disease or myocardial infarction within 6 months prior to Baseline/Day 1.
* History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect interpretation of the results of the study, or renders the subject at high risk from treatment complications.
* Women of childbearing potential without contraception, women who intend to breastfeed during the study. All subjects (both men and women) of childbearing potential who are unwilling to use adequate birth control measures during the course of the study.
* Renal failure requiring dialysis or renal transplant.
* Participation in an investigational study within 30 days prior to Screening/Visit 1 that involved treatment with any drug (excluding vitamins and minerals) or device.
* Known serious allergy to the fluorescein sodium for injection in angiography or Verteporfin.
* Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality.
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odessa National Medical University
OTHER
Mykolaiv Region Ophthalmogical Hospital
OTHER
Central Polyclinic of Internal Affairs of Ukraine
OTHER_GOV
The Filatov Institute of Eye Diseases and Tissue Therapy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrii Korol, MD, PhD
Head of Laser Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrii MD Korol, PhD
Role: PRINCIPAL_INVESTIGATOR
The Filatov Institute of Eye Diseases and Tissue Therapy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odessa National Medical University
Odesa, Please Select, Ukraine
CPUkraine
Kyiv, , Ukraine
Mykolaiv Region Ophthalmogical Hospital
Mykolaiv, , Ukraine
The Filatov Institute of Eye Diseases and Tissue Therapy
Odesa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
V Pasyechnikova N, A Naumenko V, R Korol A, S Zadorozhnyy O, B Kustrin T, O Nasinnyk I. Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach. Med Hypothesis Discov Innov Ophthalmol. 2012 Winter;1(4):72-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0118U001612/4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.